TY - JOUR
T1 - Hypersensitivity to Opioids
T2 - Prevalence, Mechanisms, Diagnosis and Management
AU - Skov, Kenneth
AU - Sædder, Eva Aggerholm
AU - Madsen, Gitte Krogh
AU - Uhrbrand, Peter Gaarsdal
AU - Eiset, Andreas Halgreen
AU - Garvey, Lene Heise
N1 - Publisher Copyright:
© 2025 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd.
PY - 2026/2
Y1 - 2026/2
N2 - Many patients report being allergic to opioids and/or have allergy warnings documented in their medical records. However, the reasoning behind these warnings is often unclear and frequently lacks clinical validation. Reported reactions may include skin rashes, itching, severe vomiting, fainting or respiratory arrest occurring during postoperative recovery where opioids were administered. In many cases, there is also uncertainty about which specific opioid was used. An allergy warning to one opioid further raises the question of whether the patient can tolerate other opioids. In this review, we address the exceedingly rare IgE-mediated opioid allergy and cross-reactivity between opioids, along with non–immune-mediated histamine release and other adverse effects of opioids that patients or clinicians may mistake for allergic reactions. We propose a simple risk stratification algorithm for the clinical management of patients labelled as opioid allergic—helping to distinguish who should be referred for allergy evaluation and who can safely be treated with opioids with or without antihistamine pre-treatment.
AB - Many patients report being allergic to opioids and/or have allergy warnings documented in their medical records. However, the reasoning behind these warnings is often unclear and frequently lacks clinical validation. Reported reactions may include skin rashes, itching, severe vomiting, fainting or respiratory arrest occurring during postoperative recovery where opioids were administered. In many cases, there is also uncertainty about which specific opioid was used. An allergy warning to one opioid further raises the question of whether the patient can tolerate other opioids. In this review, we address the exceedingly rare IgE-mediated opioid allergy and cross-reactivity between opioids, along with non–immune-mediated histamine release and other adverse effects of opioids that patients or clinicians may mistake for allergic reactions. We propose a simple risk stratification algorithm for the clinical management of patients labelled as opioid allergic—helping to distinguish who should be referred for allergy evaluation and who can safely be treated with opioids with or without antihistamine pre-treatment.
KW - adverse reactions
KW - allergy evaluation
KW - allergy labels
KW - hypersensitivity
KW - morphine
KW - MRGPRX2
KW - opioids
UR - http://www.scopus.com/inward/record.url?scp=105025873058&partnerID=8YFLogxK
U2 - 10.1111/bcpt.70182
DO - 10.1111/bcpt.70182
M3 - Review
C2 - 41447100
AN - SCOPUS:105025873058
SN - 1742-7835
VL - 138
JO - Basic and Clinical Pharmacology and Toxicology
JF - Basic and Clinical Pharmacology and Toxicology
IS - 2
M1 - e70182
ER -